About Us:

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for patients living with rare genetic diseases of obesity. Early-onset severe obesity may result from genetic variants within the melanocortin-4 receptor (MC4R) pathway, a key hypothalamic pathway that regulates hunger, caloric intake, and energy expenditure, consequently affecting body weight. Setmelanotide, an MC4R agonist, has shown the potential to restore impaired pathway function.

Setmelanotide was approved by the FDA in late 2020 for the treatment of obesity due to a deficiency in one of three genes. Rhythm is advancing a broad clinical development program with Phase 2 and 3 trials evaluating setmelanotide for the treatment of obesity due to a deficiency in one of 36 additional genes associated with the MC4R pathway. Rhythm has created and is leveraging the largest known obesity DNA database – with approximately 37,500 sequencing samples as of January 2021 – with the goal of improving the understanding, diagnosis, and care of patients with severe obesity due to certain genetic deficiencies.

For healthcare professionals, visit www.UNcommonObesity.com for more information. For patients and caregivers, visit www.LEADforRareObesity.com for more information. The company is based in Boston, MA.


Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116



Have questions? Please contact:


Enter the MAP Spotlight Raffle